Clinical Efficacy of Spleen and Yin Prescription in the Treatment of Primary Sjogren Syndrome and Its Impact on Disease Activity

Abstract

Objective: To study the clinical efficacy of primary Sjogren syndrome and the effect of disease activity. Methods: The 60 patients from January 2021 to January 2022 respectively, and divided into two groups according to random numbers, hydroxychloroquine sulfate, 30 patients, clinical effect combined with hydroxychloroquine sulfate, inflammatory index, complement levels, and immunoglobulins (ESR, RF, CRP, C3, C4, IgG, IgA, IgM), ESSDAI, ESSPRI, and adverse effects. Results: The total response rate of the two groups was 86.67% (26/30) and 73.33% (22/30), respectively, comparing with the treatment group (P <0.05). Comparison between groups found that no differences in CRP, C4, IgA, and IgM were significant (P>0.05). After treatment, peripheral ESR, RF, IgG decreased, complement C3 levels increased (P <0.05), the ESSDAI score and ESSPRI score of the two groups also decreased (P<0.05). On the Traditional Chinese medicine symptom integral, the treatment group had better results in improving dry mouth, dry throat, dry eyes, dry skin, five upset heat, and joint pain(P<0.05), and no adverse reactions were found in either group. Conclusion: The treatment group can effectively improve the clinical efficacy, reduce the level of inflammatory indicators and disease activity, and see no obvious adverse reactions, which can be effectively used in clinical practice.